- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07801066
Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer
A Prospective, Randomized, Single-blind, Study to Assess Drowsiness, Cognition, Fall Risk, and Electroencephalographic (EEG) Dynamics After Oral Metaxalone Tablets 640 mg (M640) Versus Metaxalone 800 mg in Healthy Participants
Health participants take a single dose, perform testing, washout for one week, take a single dose of different formulation, and perform testing for comparison of the 2 doses.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Healthy participants will take one dose of a drug after eating a meal. When the drug is at the highest level in their blood, testing for drowsiness and the risk of falling will take place. Brain wave monitoring known as an EEG will take place throughout the testing. Participants will take a second dose of the drug with the same testing one week later.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
- Navn: Project Manager
- Telefonnummer: 480-483-1410
- E-mail: mshahbandar@primusrx.com
Undersøgelse Kontakt Backup
- Navn: Clinical Manager
- Telefonnummer: 480-250-6689
- E-mail: msanstead@primusrx.com
Studiesteder
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43213
- Rekruttering
- AMR Clinical - Columbus
-
Kontakt:
- Site Manager
- Telefonnummer: 614-683-5800
- E-mail: jim.sanders@amr-clinical.com
-
Kontakt:
- Study Coordinator
- Telefonnummer: 614-683-5800
- E-mail: kim.burmane@amr-clinical.com
-
Ledende efterforsker:
- Harold Green, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy adults aged 18 to 55 years old
- Weigh at least 120 pounds
- Medically healthy
- Able to sign and date informed consent form
Exclusion Criteria:
- Current use of any medications known to affect the sleep-wake cycle
- Sleep disorder diagnosis
- Positive urine test for drugs
- Known history of alcohol use disorder
- Having a history of cognitive disorders, depression, schizophrenia, panic disorder, or dementia
- Having difficulty eating high fat meal
- Participants who are pregnant, nursing or intending to become pregnant during the period of study.
- Blood Pressure > 160/110 or <90/50 mmHg.
- Heart Rate >100 or < 50/ beats per minute.
- Having a history of seizure disorder or epilepsy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Active metaxalone m640 mg
One dose administered after a standard meal with testing Baseline dose to time of maximum concentration (Tmax) |
Dose micronized 640 mg
Andre navne:
|
|
Aktiv komparator: Active metaxalone 800 mg
One dose administered after a standard meal with testing Baseline dose to time of maximum concentration (Tmax) |
The dose is 800 mg
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline to approximately 4 hours post-dose, in mean reaction time to a stimulus as measured in milliseconds by the Reaction Time Test (RTT)
Tidsramme: Baseline dose to four (4 ) hours post-dose
|
Measures the time between a visual stimulus and response, measured in milliseconds |
Baseline dose to four (4 ) hours post-dose
|
|
Change from baseline to approximately 4 hours post-dose of delayed response exceeding a predefined threshold >300 ms as measured by the Reaction Time Test (RTT)
Tidsramme: Baseline dose to approximately 4 hours post-dose
|
measures the time between a visual stimulus and response, measured in milliseconds |
Baseline dose to approximately 4 hours post-dose
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: James Lukban, D.O., Primus Pharmaceutical, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PMMD-02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
No plan for publication at this time.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .